肖志坚，主任医师，教授，博士生导师，副所院长、MDS诊疗中心主任，病理中心主任。主要研究髓系肿瘤发病分子机制和临床诊治新策略。主持国家级、省部级、院校级课题共计27项。牵头制定了疾病诊治指南/共识共8部，制定了国家卫健委颁布的骨髓增生异常综合征（MDS）和骨髓增殖性肿瘤（MPN）的诊疗路径。在国际顶尖期刊N Engl J Med、Cancer Discov、Leukemia、Blood等杂志发表多篇论文，相关研究成果被国际指南引用。现为我国MDS和MPN研究领域的领军人物。

髓系肿瘤发病分子机制和临床诊治新策略。

1. Liu YC#, Kwon J#, Fabiani E#, Xiao Z#, Liu YV, Follo MY, Liu J, Huang H, Gao C, Liu J, Falconi G, Valentini L, Gurnari C, Finelli C, Cocco L, Liu JH, Jones AI, Yang J, Yang H, Thoms JAI, Unnikrishnan A, Pimanda JE, Pan R, Bassal MA, Voso MT, Tenen DG*, Chai L*. Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy. N Engl J Med. 2022,386(21):1998-2010. (IF=176.079)

2. Liu D#, Xu Z#, Zhang P, Qin T, Sun X, Qu S, Pan L, Ma J, Cai W, Liu J, Wang H, Sun Q, Shi Z, Huang H, Huang G, Gale RP, Li B*, Rampal RK*, Xiao Z*. Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center. Haematologica. 2022,107(4):991-995. (IF=11.0479)

3. Liu D#, Li B, Xu Z, Zhang P, Qin T, Qu S, Pan L, Sun X, Shi Z, Huang H, Wang H, Gale RP, Xiao Z*. RBC distribution width predicts thrombosis risk in polycythemia vera. Leukemia. 2022,36(2):566-568. (IF=12.883)

4. Liu D#, Xu Z, Zhang P, Qin T, Li B, Qu S, Pan L, Cai W, Liu J, Wang H, Sun Q, Sun X, Jiao M, Gao Q, Shi Z, Huang H, Huang G, Gale RP, Xiao Z*. Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera. Blood Cancer J. 2021,11(9):154. (IF=9.812)

5. Huang H#, Xu C#, Gao J#, Li B, Qin T, Xu Z, Ren S, Zhang Y, Jiao M, Qu S, Pan L, Hu N, Liu J, Cai W, Zhang Y, Wu D, Zhang P, Gale RP, Huang G, Zhou J, Shi L*, Xiao Z*. Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre. Blood Cancer J. 2020,10(8):83. (IF=11.037)

6. Hayashi Y#, Zhang Y#, Yokota A#, Yan X, Liu J, Choi K, Li B, Sashida G, Peng Y, Xu Z, Huang R, Zhang L, Freudiger GM, Wang J, Dong Y, Zhou Y, Wang J, Wu L, Bu J, Chen A, Zhao X, Sun X, Chetal K, Olsson A, Watanabe M, Romick-Rosendale LE, Harada H, Shih LY, Tse W, Bridges JP, Caligiuri MA, Huang T, Zheng Y, Witte DP, Wang QF, Qu CK, Salomonis N, Grimes HL, Nimer SD, Xiao Z*, Huang G*. Pathobiologic Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. Cancer Discov, 2018, 8(11):1438-1457. (IF=26.37)

7. Luo X#, Xu Z#, Li B#, Qin T, Zhang P, Zhang H, Fang L, Pan L, Hu N, Qu S, Zhang Y, Huang G, Peter Gale R, Xiao Z*. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. Blood Cancer J. 2018,8(1):9. (IF=7.895, R)

8. Wang J#, Xu Z#, Liu L#, Gale RP, Cross NC, Jones AV, Qin T, Ai X, Xu J, Zhang T, Sun X, Li Q, Zhang P, Zhang Y, Xiao Z*. JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. Leukemia,2013,27(8):1763-1767. (IF=9.379)

9. Xu Z#, Gale RP, Zhang Y, Qin T, Chen H, Zhang P, Zhang T, Liu L, Qu S, Xiao Z*. Unique features of primary myelofibrosis in Chinese. Blood. 2012,119(11):2469-73. (IF=9.060, F1000)

10. Xiao Z#*, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma. 2002,43(9):1763-8. (IF=1.335, C100)